Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067

Value in Health- United Kingdom

doi 10.1016/j.jval.2017.08.218

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

Clinical Cancer Research
Cancer ResearchOncology
2016English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy